Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Bora Pharmaceuticals also offers lyophilization, terminal sterilization, analytical, stability, and packaging and serialization services.

Phase I trial patients experienced shrinkage of brain tumors and extended survival rates beyond the standard prognosis of one ...

Therapeutic plasma exchange combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as ...

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Fetal bovine serum (FBS) has long served as a foundational input for cell culture, tissue engineering, and biomanufacturing.

The IDMO Smart Factory initiative has the potential to help advance the development and approval of CAR-T therapeutics in ...

A decades-old TB vaccine turned cancer therapy may unlock new immunotherapies by reprogramming immune cell development in the ...

Mouse models treated with the sleep aid lemborexant had less brain damage compared to controls and mice that received a ...

The latest imaging method from the Broad Institute uncovers structural disruptions in the nucleus associated with progeria at ...

Replacing PEG with PCB in lipid nanoparticles led to potent mRNA vaccines that avoided unwanted immune responses.